XiaoMi-AI文件搜索系统
World File Search Systemsimilar
2024公司责任报告
前瞻性陈述本公司责任报告中提供的信息（“报告”）包括旨在根据我们当前的观点和假设来表达预期结果的前瞻性陈述。结果，这些前瞻性陈述受到许多风险，不确定性以及未来事件的结果，这些风险可能会导致实际结果，绩效或成就，从而与本报告中表达，预测或暗示的结果有重大不同。Forward-looking statements are typically identified by using words such as “may,” “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project,” “target,” “goal,” “plan,” “should,” “will,” “predict,” “potential,” “strategy” and similar expressions that convey the uncertainty of future events or the unpredictability of outcomes.这些前瞻性陈述包括但不限于我们所采取的未来行动，管理计划，目标和目标，未来的支出，公司结构以及收购和处置策略。
Luminor银行临时报告4Q 2024
1。Material accounting policy information ..................................................................................................................................................... 18 2.General risk management policies ............................................................................................................................................................ 20 3.Net interest and similar income .................................................................................................................................................................. 21 4.Net fee and commission income ............................................................................................................................................................... 22 5.Net gain from financial instruments at fair value .................................................................................................................................... 24 6.Other operating expense - net .................................................................................................................................................................. 24 7.Other administration expenses .................................................................................................................................................................. 24 8.Bank taxes and resolution fee .................................................................................................................................................................... 24 9.Debt securities ............................................................................................................................................................................................... 25 10.Loans to customers ...................................................................................................................................................................................... 26 11.Intangible assets .............................................................................................................................................................................................31 12.Other assets ................................................................................................................................................................................................... 32 13.Deposits from customers ............................................................................................................................................................................ 33 14.Debt securities issued .................................................................................................................................................................................. 33 15.Other liabilities ............................................................................................................................................................................................... 34 16.Contingent liabilities ..................................................................................................................................................................................... 34 17.Derivatives ...................................................................................................................................................................................................... 35 18.Fair value of financial instruments ............................................................................................................................................................. 36 19.Customer segments...................................................................................................................................................................................... 38 20.Related parties.............................................................................................................................................................................................. 40 21.Country information ..................................................................................................................................................................................... 41 Additional Information ........................................................................................................................................................................................... 42
振兴抗病毒武器
本演讲可能包含根据1995年《私人证券诉讼改革法》的安全港规定的前瞻性陈述。These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts”, “goal,” “intends,” “may” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements.本演示文稿中包含的历史事实陈述以外的所有陈述都是前瞻性陈述，包括有关以下陈述：我们的未来财务或业务绩效，条件，计划，计划，趋势或策略以及其他财务和商业事务；我们目前和潜在的产品候选人；肿瘤学上自行车的治疗潜力；计划的临床试验和临床前活动；当前和潜在的合作；以及我们发展预期产品候选人的时间和成功。
分子技术和系统医学的CEMM国际博士学位课程•您想在促进自由思考的环境中工作
You are: + an exceptionally motivated PhD candidate with a keen interest in interdisciplinary teamwork and science that nurtures the precise, personalized, predictive and preventive medicine of the future + excellent in writing and speaking English + a candidate with (or obtaining by September 2024) a final degree in medicine, biology, chemistry, bioinformatics, computer science, engineering, physics, mathematics or a similar subject (minimum requirement is a具有荣誉的四年学士学位）研究领域2024 CEMM博士学位计划将重点关注感染，免疫，代谢，癌症，罕见疾病，网络医学，设计化学，患者衍生的器官和衰老研究的主题领域。这些区域建立在表观遗传学和基因组完整性，生物信息学和系统生物学，高通量遗传学，基因组学和蛋白质组学，分子和细胞生物学，高含量自动成像，化学生物学和有机化学化学合成的支柱上。
1线粒体总是显示为椭圆形
线粒体形态的研究更多地是在培养的细胞而不是天然细胞中进行的。The issue with this disparity has been highlighted by a study of vascular smooth muscle cells, of which those that were cultured cells appeared to offer more mitochondrial morphological diversity than in those that are native, which rather have singular spherical or rod-like mitochondria (with native cells in most tissues being found to have these similar, punctuate mitochondria), making it unlikely that observing ovoid shapes is due to氧化应激或成像难度。进一步的证据表明，遵守线粒体形状的传统观念包括未发现天然细胞的线粒体是电耦合的 - 它们的膜电位变化是独立的，而不是作为公共变化的一部分，这将在形成连续网络的细胞器中观察到。图1介绍了这项研究中线粒体和培养细胞中线粒体的图像。
机器人sapocococopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopex
机器人sapocococolecopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopexy是一种用于泌尿生殖器脱垂的手术管理的高级侵入性技术。与传统方法相比，它具有卓越的精度，减少的失血和降低的转化率。但是，较长的手术时间，更高的成本和对专业培训的需求仍然是机器人手术最重要的挑战。与传统方法相比，机器人sapocrococococopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopopexy。但是，描述的是涉及更长的手术时间，成本增加以及对专业培训的需求。此外，该技术显示出减少肥胖患者并改善美容结果的并发症的显着潜力。Comparative studies highlight that robotic and laparoscopic sacrocolpopexy yield similar long-term outcomes, with differences primarily in operative time and cost-ef fi ciency robotics.缺乏标准化协议仍然是一个限制，需要关于耐用性和成本效益分析的长期数据。未来的研究应优先考虑优化结果，降低成本并提高对机器人泌尿瘤手术的可及性。
最终报告影响大型能源用户计划（LEUP）的项目在2021 - 2022年完成的项目
表AB-1的表列表。Summary of LEUP retrospective first year savings ................................................................................................ i Table AB-2.Summary of LEUP retrospective lifetime savings ................................................................................................... i Table AB-3.Consolidation and summary of recommendations ................................................................................................ ii Table ES-1.Summary of LEUP retrospective first year savings ............................................................................................... 2 Table ES-2.Summary of LEUP retrospective lifetime savings .................................................................................................. 2 Table ES-3.Prospective first year savings ................................................................................................................................ 3 Table ES-4.Prospective lifetime savings .................................................................................................................................. 4 Table 1-1.Summary of achieved objectives and approaches to each evaluation ..................................................................... 5 Table 2-1.Summary of sample design ...................................................................................................................................... 9 Table 4-1.Summary of first year LEUP retrospective savings ................................................................................................ 11 Table 4-2.终生LEUP回顾性总终身节省结果的摘要........................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 11表4-3。Electric first-year savings results discrepancy by category .................................................................................... 13 Table 4-4.Natural gas first-year savings results discrepancy by category .............................................................................. 13 Table 4-5.Prospective first year savings ................................................................................................................................ 15 Table 4-6.Prospective lifetime savings ................................................................................................................................... 15 Table 4-7.Electric lifetime savings results discrepancy by category ....................................................................................... 16 Table 4-8.Natural gas lifetime savings results discrepancy by category ................................................................................ 16 Table 4-9.Summary of evaluated industrial measures with associated EULs ........................................................................ 18 Table 4-10.Changes in lifetime savings due to prospective evaluation metrics for electricity ................................................ 19 Table 4-11.NTG results .......................................................................................................................................................... 20 Table 4-12.Jurisdictional comparison of NTGRs .................................................................................................................... 20 Table 4-13.LEUP计划的样本合格商业客户............................................................................................................................................................................................................................................................................................................................................... 25表5-1。 Large custom and similar programs from other states, process findings ............................................................... 28 Table 6-1. Summary of LEUP first year retrospective evaluation savings ............................................................................... 30 Table 6-2. LEUP回顾性终身评估节省的摘要............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 30LEUP计划的样本合格商业客户............................................................................................................................................................................................................................................................................................................................................... 25表5-1。Large custom and similar programs from other states, process findings ............................................................... 28 Table 6-1.Summary of LEUP first year retrospective evaluation savings ............................................................................... 30 Table 6-2.LEUP回顾性终身评估节省的摘要............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 30
结论 定性分析显示，爱气疗法对各种患者群体都具有良好的效果。大部分研究发现，爱气疗法在平衡、疼痛、功能性活动和生活质量方面的效果优于陆地干预，与替代性水上干预相比，其效果相似。值得进一步研究。
桑塔纳 19 纤维肌痛 9 4/10 VAS FIQ 卡米洛蒂 22 背痛 29 4/10 VAS** ODI** 缩写：6MWT，6 分钟步行测试；ABC，活动特定平衡信心量表；BBS，伯格平衡量表；BDI，贝克抑郁量表；FIQ，纤维肌痛影响问卷；FSS，疲劳严重程度量表；FTSST，五次坐站测试；GDS，老年抑郁量表；MPQ（PPI/PRI），麦吉尔疼痛问卷（PPI，当前疼痛强度；PRI，当前评分指数）；MFIS（Ph/Co/PS），改良疲劳影响量表（Ph=身体，Co=-认知，PS=-社会心理）； MSIS-29-Ps/Ph，多发性硬化症影响量表-29（Ps=心理，Ph=身体）；NPRS，数字疼痛评定量表；ODI，奥斯沃斯特里残疾指数；PDQ-39，帕金森病问卷-39；PSQI，匹兹堡睡眠质量指数；SF-12，12 项简明健康调查表；SL，步幅：ST，步幅时间；STAI，状态与特质焦虑量表；TUG，计时起立行走；UPDRS，统一帕金森病评定量表；VAS，视觉模拟量表；^ 爱驰组比对照组有更好的改善，^^ 爱驰与对照组有相似的结果，^^^ 对照组比爱驰组有更好的结果，* p<0.5，** p<0.01，***p<0.001
Selective Growth of GaP Crystals on CMOS-Compatible Si Nanotip Wafers by Gas Source Molecular Beam Epitaxy
ABSTRACT: Gallium phosphide (GaP) is a III − V semiconductor with remarkable optoelectronic properties, and it has almost the same lattice constant as silicon (Si). However, to date, the monolithic and large-scale integration of GaP devices with silicon remains challenging. In this study, we present a nanoheteroepitaxy approach using gas-source molecular-beam epitaxy for selective growth of GaP islands on Si nanotips, which were fabricated using complementary metal − oxide semiconductor (CMOS) technology on a 200 mm n-type Si(001) wafer. Our results show that GaP islands with sizes on the order of hundreds of nanometers can be successfully grown on CMOS-compatible wafers. These islands exhibit a zinc-blende phase and possess optoelectronic properties similar to those of a high-quality epitaxial GaP layer. This result marks a notable advancement in the seamless integration of GaP- based devices with high scalability into Si nanotechnology and integrated optoelectronics. ■ INTRODUCTION
2024 年消灭脊髓灰质炎跨境协调计划
The global polio programme aims to eradicate wild poliovirus transmission in endemic countries, stop variant poliovirus transmission and prevent outbreaks in all countries by December 2028.The African Region has shown its capability by ending indigenous wild poliovirus (WPV) transmission and stopping WPV outbreak following importation. In 2024, the Region developed the Africa Regional Polio Eradication Action Plan 2024–2025. This plan outlines a bold strategy to end polio outbreaks across the WHO African Re gion by moving beyond the standard response to more intensive efforts, similar to what it took to end wild polioviruses in the Region. The timeline to reach the goals is phased across epidemiological zones, with the aim to end all active variant poliovirus type 1 outbreaks by December 2024 and all active variant poliovirus type 2 outbreaks by December 2025.